Fierce Pharma1d
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Targeted Oncology2d
HER2 Therapies Redefine Brain Metastasis Treatment in Breast Cancer
Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...
pharmaphorum4d
Breast cancer drug Perjeta launched for early use – but UK access uncertain
Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
pharmaphorum3d
After a nay from NICE, Scotland says aye to J&J’s Spravato
The SMC issued a green light for use by NHS Scotland of Roche’s Perjeta (pertuzumab) as an adjuvant (post-surgery) treatment to prevent relapse in patients with HER2-positive early-stage breast ...